PFE: Summary for Pfizer, Inc. Common Stock - Yahoo Finance

UK Markets closed

Pfizer Inc. (PFE)


NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
31.77+0.07 (+0.22%)
At close: 4:01PM EST
People also watch
MRKJNJJPMGEINTC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close31.70
Open31.72
Bid0.00 x
Ask0.00 x
Day's range31.66 - 32.12
52-week range28.25 - 37.39
Volume30,159,695
Avg. volume28,035,072
Market cap192.79B
Beta0.99
PE ratio (TTM)31.90
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield1.28 (4.03%)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • How Will Pfizer Inc. Fare Under President Trump?
    Motley Fool23 hours ago

    How Will Pfizer Inc. Fare Under President Trump?

    From drug pricing to tax reform, here's how Pfizer could be impacted by President Trump's proposals.

  • Kiplingeryesterday

    10 Best Dividend-Paying Stocks for 2017

    High-quality dividend stocks never go out of style for long-term investors, and there is no shortage of stocks with high yields and bright prospects for 2017, from telecommunications companies embracing the digital future to pharmaceutical companies riding the success of new drugs. The pharmaceutical sector is a great place to look for generous dividend payers and few stocks sport yields as high as AbbVie's. The patent expired in December on AbbVie's Humira, the top-selling anti-inflammatory drug on the market. AbbVie's shares returned 20%, including dividends, over the past 52 weeks, while the pharmaceutical sector overall was in the red.

  • Amgen Could Gouge 'Top Pick' AbbVie With Humira Biosimilar: Jefferies
    Investor's Business Daily2 days ago

    Amgen Could Gouge 'Top Pick' AbbVie With Humira Biosimilar: Jefferies

    Roche, Merck and Pfizer will likely disappoint on 2017 guidance, but AbbVie stock remains a "top pick" for Jefferies analyst Jeffrey Holford.